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Abstracts A77
Americans participants in the later stages of CKD may be associated with lack of health 
care access/ socio-economic factors. The proportion of population suffering from 
hypertension and diabetes increased signiﬁcantly from stage 1 to stage 5 along with 
marked racial disparities in the higher stages of CKD. Markers such as Vitamin D 
deﬁciency, Hypertension & serum creatinine levels can be better monitored by regular 
blood tests and prove to be effective early indicators in the progression of CKD.
URINARY/KIDNEY DISORDERS – Cost Studies
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OBJECTIVES: Non-adherence to immunosuppressants increases risk of late acute 
rejection (AR) episodes, a known predictor of graft loss, which is associated with 
re-transplantations, dialysis and increased mortality. Once-daily immunosuppressant 
formulations demonstrate higher patient adherence than multiple daily dose therapies 
and may lead to fewer AR episodes and graft losses. A model was constructed to 
estimate the ﬁve-year impact of potentially improved adherence in new renal trans-
plant recipients receiving once- rather than twice-daily tacrolimus. METHODS: The 
increased potential for sufﬁcient adherence with once-daily immunosuppressants, 
versus twice-daily, is reported as an odds ratio (OR) of 2.35 (published literature). 
The model uses a probability of sufﬁcient adherence of 74% with once-daily tac-
rolimus, determined from an assumed adherence for twice-daily tacrolimus of 55% 
and OR for adherence with once- versus twice-daily therapy. Increased adherence is 
assumed to improve consistency in tacrolimus exposure, reducing AR each year post-
transplant and improving graft survival. Sufﬁcient levels of expected adherence with 
once- and twice-daily tacrolimus are used to model ﬁve-year survival rates for: AR 
(sufﬁciently-adherent versus non-sufﬁciently-adherent patients); graft survival (no pre-
vious AR versus previous AR); patient survival (functioning graft versus dialysis). Drug 
costs include tacrolimus; co-prescribed therapies (IV and oral prednisolone and oral 
mycophenolate mofetil). Other resource use and costs considered include management 
of AR; dialysis after graft loss; re-transplantation. RESULTS: Over ﬁve years, assum-
ing 100 new renal transplant recipients annually, once-daily tacrolimus is associated 
with fewer AR episodes than twice-daily (8.4 and 10.5, respectively), due to improved 
sufﬁcient adherence. Once-daily tacrolimus yields cumulative cost savings of £104,534, 
including savings in drug acquisition (£69,180); management of AR (£22,837); re-
transplantation (£417); dialysis (£13,631). CONCLUSIONS: Use of once- rather than 
twice-daily tacrolimus reduces incidence of AR and could yield clinical improvements 
and cost savings over ﬁve-years.
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OBJECTIVES: Immunosuppressive drugs (IS) are used in combination/schemes to 
achieve optimal regimen of immunosupression, increasing graft and recipient survival 
rates in post kidney transplant patients. The aim of this study is to determine immu-
nosuppressant treatment patterns and associated costs in kidney transplant patients 
from the Brazilian National Transplant Program. METHODS: A review of the entire 
government administrative claim database (Outpatient Information System – SIA/
DATASUS) was conducted from 2005 to 2008, to determine yearly expenses (in 2008 
USD) with each IS combination. In order to assess the dynamics of the combinations 
used, a subset of this population, all patients from 7 hospitals who underwent kidney 
transplantation in 2004, was followed from January 2005 to December 2007 to 
estimate calcineurin inhibitors (CNI) switching rate and treatment adherence in terms 
of 24-month medication possession ratio (MPR). RESULTS: Analysis of the entire 
database reveals that overall IS expenses in kidney transplant patients more than 
doubled, from US$62,429,359 in 2005 to US$126,874,381 in 2008, mostly due to an 
increase in both treatment volume and costs from 2006 to 2007. From 2005 to 2007, 
monthly treatment volume increased 14.7% for cyclosporine and 62.9% for tac-
rolimus, whereas costs increased 3.2% for cyclosporine and 93.1% for tacrolimus. 
The highest ﬁnancially impacting combination per CNI were tacrolimus plus myco-
phenolate sodium (US$37,329,606 in 2008), and cyclosporine plus mycophenolate 
sodium (US$10,163,990 in 2008). A total of 540 patients were eligible for the sub-
population analysis. CNI therapy switch rate, from tacrolimus to cyclosporine or 
vice-versa was 4.3% (n = 185). MPR for CNIs was 73.7% (n = 224; SD = 21.7%). 
CONCLUSIONS: From 2005 to 2008, IS drugs expenses in post kidney transplant 
patients substantially increased in Brazil. Low CNI switching rates suggests that de 
novo patients are the main target population for newer CNIs. The poor drug adher-
ence detected is an important point of concern.
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OBJECTIVES: This study evaluated recent erythropoiesis-stimulating agent (ESA) 
utilization and costs from 2 large health insurance claims databases in chronic kidney 
disease (CKD) patients not on dialysis. METHODS: An analysis of recent medical 
claims from the Ingenix IMPACT (January 2006-March 2009) and Medicare 5% 
(January 2005-December 2007) databases was conducted. Patients ≥18 years, newly 
initiated on epoetin alfa (EPO) or darbepoetin alfa (DARB), with ≥1 claim for CKD 
and ≥2 ESA claims were included. Patients diagnosed with cancer, receiving chemo-
therapy or dialysis, or receiving both agents were excluded. Mean cumulative ESA 
dose was used to calculate drug cost (using October 2009 wholesale acquisition cost) 
and dose ratio (Units EPO: mcg DARB). Multivariate analysis was also conducted to 
assess adjusted cost differences between the two agents. RESULTS: A total of 4,678 
ESA-treated patients were identiﬁed (IMPACT—EPO: 991, DARB: 689; Medicare—
EPO: 1,788, DARB 1,210). Age and gender distributions were similar between 
the 2 groups (Mean age: IMPACT: 63.9 vs. 63.2 yrs; Medicare: 74.7 vs. 74.2 yrs, P 
= NS; % women: IMPACT: 49% vs. 54%; Medicare 59% vs. 62%, P = NS). ESA 
treatment duration was also similar for EPO and DARB patients. The mean cumulative 
dose [SD] was 164,786 [175,453] and 244,718 [304,839] Units for EPO and 
694 [690] and 989 [1,118] mcg for DARB, resulting in dose ratios of 237:1 and 247:1 
for IMPACT and Medicare data, respectively. Based on the recent utilization of 
ESAs, cumulative cost was 44% and 38% higher for DARB than EPO (IMPACT—
EPO $2380; DARB $3427; Medicare—EPO $3534; DARB $4888). After adjusting 
for covariates, cumulative drug costs remained signiﬁcantly higher for DARB. 
CONCLUSIONS: Based on large health insurance claims databases, this observational 
study of recent ESA utilization in CKD patients not on dialysis reported dose 
ratios of 237:1 and 247:1 and cost premiums of 44% and 38% associated with 
DARB.
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OBJECTIVES: This study compared drug utilization patterns and associated costs as 
well as dosing trends over time in patients with chronic kidney disease (CKD) not on 
dialysis receiving epoetin alfa (EPO) or darbepoetin alfa (DARB) through a pharmacy 
beneﬁt. METHODS: An analysis of pharmacy claims between July 2002 and March 
2009 from the Ingenix IMPACT database was conducted. Patients ≥18 years, newly 
initiated on erythropoiesis-stimulating agents (ESAs), with ≥1 claim for CKD, and ≥1 
ESA pharmacy claim were included. Patients diagnosed with cancer, receiving chemo-
therapy or dialysis, or receiving both agents were excluded. Mean cumulative ESA 
dose was used to calculate drug cost (using 10/2009 wholesale acquisition cost) and 
dose ratio (Units EPO: mcg DARB). Average weighted weekly ESA dose was calculated 
during the treatment episode to assess ESA utilization trends over time. Multivariate 
analysis was also conducted. RESULTS: A total of 4,202 ESA-treated patients were 
identiﬁed (EPO 3,111; DARB 1,091). EPO patients were slightly older (60.1 vs. 57.0, 
P < .001) with a higher Charlson Comorbidity Index (1.68 vs 1.44, P < .001). Mean 
[SD] cumulative dose was 219,060 [236,830] Units for EPO and 818 [956] mcg for 
DARB, resulting in a dose ratio of 268:1 (Units EPO: mcg DARB). The corresponding 
drug cost was 28% higher for DARB than EPO ($3163 vs. $4039, P < .001). 
From 2002 to 2009, a decreasing trend was observed in semi-annual mean weekly 
doses of ESAs [EPO: 17,053 to 13,674 Units (25% decrease); DARB: 63 to 51 mcg 
(20% decrease)]. After adjusting for potential confounding factors, the DARB cost 
premium and the decreasing weekly ESA dosing trend over time remained signiﬁcant. 
CONCLUSIONS: This study of CKD patients not on dialysis receiving ESAs through 
pharmacy beneﬁts reported signiﬁcantly higher drug costs in the DARB group 
compared with the EPO group and a decreasing ESA dosing trend during the 7-year 
study period.
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OBJECTIVES: The objective of this study is to evaluate hospitalizations, outpatient 
services and medication use in the ﬁrst year of dialysis associated with pre-dialysis 
treatment with paricalcitol compared to no predialysis vitamin D receptor (VDR) 
activator use in chronic kidney disease (CKD) patients with SHPT. METHODS: A 
matched cohort analysis was conducted in 154 hemodialysis patients comparing uti-
lization outcomes of predialysis use of paricalcitol compared to no VDR activator 
treatment, using the Medstat™ administrative claims database from 2000–2007. 
Patients were matched using propensity scoring for age, gender, Charlson co-morbid-
ity Index, and pre-index total costs. Multivariate models adjusted for age, gender, 
